Acidum dimethoxycinnamicum CAS, 2316-26-9; 6443-72-7
  • Acidum dimethoxycinnamicum CAS, 2316-26-9; 6443-72-7Acidum dimethoxycinnamicum CAS, 2316-26-9; 6443-72-7

Acidum dimethoxycinnamicum CAS, 2316-26-9; 6443-72-7

Acidum dimethoxycinnamicum CAS 2316-26-9; 6443-72-7 est monomerus a Securidaca inappendiculata extractum et purgatum. 3,4-acidum dimethoxycinnamicum effectum anti-apoptoticum in cellulis L-02 per ROS mediatum iter significantem exercet

Mitte Inquisitionem

depictio producti

Invenire ingentem selectionem acidorum 3,4-Dimethoxycinnamici CAS 2316-26-9; 6443-72-7 e Sinis ad Crede Chemical. Shandong Credite


Acidum dimethoxycinnamicum CAS 2316-26-9; 6443-72-7 Chemical Specification

Product Name

3,4-acidi dimethoxycinnamicum

Formulae

C11H12O4

M. Pondus

208.21

2316-26-9

quantitas

500KG


Items

Specification

Proventus

Aspectus

Alba ad beige

Conforms

Assay

≥ 99%

Conforms

liquescens punctum

181-183

Conforms

density

1.0627 (aestimatio aspera)

Conforms

CONCLUSIO

Effectus conformis vexillum


Acidum dimethoxycinnamicum CAS 2316-26-9; 6443-72-7 Proprietates chemicae


Synonym: RARECHEMBKHCT253;TIMTEC-BBSBB005722; OTAVA-BBBB0107620014;(2E)-3-(3,4-Dimethoxyphenyl)-2-propenoicacid;3,4-DimethoxycinnaChemicalbookmicacid98%;Caffeicaciddimethylether; -DiMethoxycinnaMicacid,99%5GR

CAS;

Formulae hypotheticae:

Pondus hypotheticum:

EINECS: 219-025-5

Repono conditionibus: signatus in siccis, volutpat Temperature

Vita fasciae: 2 years


Acidum dimethoxycinnamicum CAS 2316-26-9; 6443-72-7 Chemical

Ad pharmaceuticam intermedia et organica synthesin intermedia



Hot Tags: Acidum Dimethoxycinnamicum CAS 2316-26-9; 6443-72-7, Manufacturers, Suppliers, Tutus, Factory, In Stock, In Sinis, Sinis, Cheap, Discount, Quality, API, Investigationis et Progressus, Consuetudinis Synthesis.

Related Categoria

Mitte Inquisitionem

Libenter placet, ut inquisitionem tuam in forma infra exhibeas. Respondebimus tibi in 24 horis.
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept